Camber’s generic will be available in 20-, 40-, and 80-mg dosage strengths and packaged in 3x10 blister cards.
The drug is indicated as an adjunctive therapy to relieve discomfort associated with acute, painful musculoskeletal conditions.
This launch marks the seventh product ANI has re-commercialized after acquiring a portfolio of discontinued generic abbreviated new drug applications.
The company said that this marks its fourth first-to-market generic launch since June 2016.
The drug had U.S. sales of $15 million for the 12 months ended April 2017, Perrigo said.
National Community Pharmacists Association CEO Doug Hoey writes about the role pharmacists are playing in helping combat the nation’s prescription drug abuse epidemic.
The company said it will be splitting its customer-facing businesses into two divisions, and it has created a new management committee to facilitate faster decision-making.
Testing will be available at more than 220 participating Walgreens stores in 130 cities.